Trial reportClinical cancer research : an official journal of the American Association for Cancer Research2026
A Randomized, Phase II Clinical Trial of FLT-PET and FDG-PET for Early Response Assessment of Neoadjuvant Systemic Therapy in Triple-Negative Breast Cancer.
Trial report in Clinical cancer research : an official journal of the American Association for Cancer Research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
Abstract
purposeEarly identification of response to neoadjuvant chemotherapy (NACT) in triple-negative breast cancer (TNBC) can facilitate timely treatment adjustments. This phase II analytic and clinical validity study (TNPET01) evaluated whether [18F]-fluorodeoxyglucose (FDG) or [18F]-fluorothymidine (FLT) positron emission tomography (PET)/CT can predict response after one NACT cycle. PATIENTS AND
methodsIn part A (analytic validity phase), patients with stage II-III TNBC were randomized to FDG or FLT imaging. Baseline repeat scans assessed test-retest repeatability, followed by a post-cycle 1 scan in week 3. Dynamic imaging preceded static acquisitions at 90-, 120-, and 180-minute (FDG) or 90-minute (FLT), evaluating SUVmax, SUVmean, SUVpeak, and SULpeak. Tracer selection for part B was based on prespecified repeatability and response criteria. Part B (clinical validity phase) examined associations between changes in SUV (ΔSUV) after one cycle and post-cycle 3 MRI, end-of-treatment MRI, and residual cancer burden (RCB) at surgery. Exploratory analyses assessed relationships between PET response, Ki-67, and tumor-infiltrating lymphocytes (TIL).
resultsTwenty-two patients were enrolled. Both tracers met repeatability thresholds; FDG was selected for part B owing to superior image quality and availability. Fourteen patients underwent FDG-PET across both parts. Reductions in SUVmax/mean after one cycle significantly correlated with mid-treatment MRI response and final RCB score (P < 0.005). Early post-cycle 1 increases in TILs correlated with greater metabolic reduction and lower RCB, whereas Ki-67 changes were not predictive.
conclusionsFDG-PET after one NACT cycle was associated with histologic response and stronger correlations with RCB than MRI. These findings support PET as an early biomarker for treatment response and warrant validation in larger, immunotherapy-era trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.